Submit Deal

BLACKSTONE LIFE SCIENCES

HQ - Massachusetts

Summary

Blackstone Life Sciences is a private investment platform investing in companies and products within key life science sectors.

Deals Overview

Total Deals4

Valued Deals4

Total Value£ 2.97 B

Avg. Deal Size£ 743 M

Market Context

Parent Company

BLACKSTONE GROUP INC

583 transactions

Senior Management

Paris Panayiotopoulos
Managing Director
Kiran Reddy
‎Senior Managing Director
Nick Galakatos
Global Head of Life Sciences

Sort

11 Jun 2020|United States|Pharmaceuticals

Target: REATA PHARMACEUTICALS INC

Bidder: BLACKSTONE GROUP INC

4 Service Providers

2 Target | 2 Bidder

34 Dealmakers

32 Target | 2 Bidder

£ 280 M

Value

22 Oct 2024|United States|Biotechnology

Target: AVENCELL THERAPEUTICS

Bidder: NYBC VENTURES

4 Service Providers

2 Target | 2 Bidder

8 Dealmakers

6 Target | 2 Bidder

£ 86 M

Value

11 Feb 2025|United States|Biotechnology

Target: ANTHOS THERAPEUTICS

Bidder: NOVARTIS AG

8 Service Providers

5 Target | 1 Bidder | 2 Vendor

19 Dealmakers

4 Target | 3 Bidder | 12 Vendor

£ 2.50 B

Value

27 May 2025|United States|Biotechnology

Target: GRIN THERAPEUTICS

Bidder: ANGELINI PHARMA

4 Service Providers

1 Target | 3 Bidder

17 Dealmakers

2 Target | 15 Bidder

£ 103 M

Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy